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Systemic sclerosis (SSc) is an autoimmune sys-temic disease characterized by systemic inflam-mation, vascular abnormalities, and fibrosis of 
the skin and internal organs.1 Two forms of SS have 
been described: diffuse cutaneous systemic sclero-
sis (DcSSc) and limited cutaneous systemic sclerosis 
(LcSSc). Patients with LcSSc may display features of 
the CREST syndrome (calcinosis cutis, Raynaud phe-
nomenon, esophageal dysmotility, sclerodactyly, and 
telangiectasia).2 An increased risk of cancer in SSc pa-
tients had been reported in retrospective studies, with 
reports of lung and breast cancers being dominant.3-8 
Around 30 cases of non-Hodgkin lymphomas (NHL) 
were reported in association with SSc, in both DcSSc 
and LcSSc subsets.9 To our knowledge, there has been 
no report of small lymphocytic lymphoma (SLL) in as-
sociation with LcSSc/CREST syndrome. 
CASE
A 61-year-old white man was referred to our clinic for 
evaluation of thrombocytopenia. He had had Raynaud 
disease and thickening on the skin of his hands along 
with telangiectatic changes on his face for the past 30 
years, yet he was diagnosed with CREST syndrome 
only 1 year before being referred to us. At that time, he 
presented with worsening exertional dyspnea and was 
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We report a case of a 61-year-old man with a history of CrEst syndrome (calcinosis cutis, raynaud 
phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) who presented for evaluation 
of thrombocytopenia. he had evident cervical adenopathy and lymph node biopsy showed small lym-
phocytic lymphoma (sLL) with evident systemic adenopathy and bone marrow involvement. the patient 
achieved a complete remission with fCr (fludarabine/cyclophosphamide/rituximab) chemotherapy. 
about 30 cases of lymphomas are reported in the literature in association with systemic sclerosis. to 
our knowledge, there are no reports of a small lymphocytic lymphoma (sLL) in association with limited 
cutaneous systemic sclerosis with classic features of the CrEst syndrome.
found to have evidence of interstitial lung disease and 
severe pulmonary hypertension. He underwent a trans-
bronchial lung biopsy that showed pulmonary endo-
thelialitis. He also reported acid reflux symptoms and 
had an upper endoscopy that showed Barrett esophagus 
(with high-grade dysplasia). His ANA titer was 1:160 
with a centromeric pattern yet he had a negative anti-
centromere antibody, negative ENA screen and a nega-
tive Scl-70 antibody. He was started on mycophenolate 
mofetil along with sildenafil. Because of worsening pul-
monary functions, mycophenolate mofetil was changed 
to cyclophosphamide. We held his cyclophosphamide 
and his platelet count did not improve significantly. 
We also noted that the patient had a few small cervical 
lymph nodes. The patient denied B symptoms. Biopsy 
of these nodes revealed small lymphocytic lymphoma 
(SLL) (Figure 1). The neoplastic cells were positive 
for CD5, CD19, CD20(dim), CD23(partial), surface 
kappa light chains, and negative for cyclin D1. Lactate 
dehydrogenase was not elevated. Total body CT scan 
showed small medistinal, hilar, axillary, retroperito-
neal, and inguinal adenopathy (Figure 2). Additionally, 
fatty hepatomegaly, no splenomegaly, and inflamma-
tory changes were noted in the lungs. Bone marrow 
biopsy revealed 40% cellular marrow with 5% to 10% 
involvement with lymphoid aggregates (Figure 3), and 
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with clonal lymphocytes expressing the same immuno-
phenotype seen on lymph node biopsy. About 55% of 
the CD5+/CD19+ clonal population also expressed 
CD38. Megakaryocytes were adequate numerically and 
morphologically within normal limits. Cytogenetic/
FISH analysis revealed deletion of 13q14 (5%) and de-
letions of 11q22.3 and 17p13.1 (4%) of the interphase 
cells from the bone marrow specimen. After treatment 
with 3 cycles of fludarabine (25 mg/m2 on day 1-3), cy-
clophosphamide (200 mg/m2 on day1-3), and rituximab 
(375 mg/m2 on day 1), the patient achieved a complete 
remission yet no further chemotherapy could be given 
because of protracted thrombocytopenia. Repeat bone 
marrow biopsy after chemotherapy showed a hypocellu-
lar marrow (10%), only 0.2% clonal B-cells (only seen on 
flow cytometry), and decreased megakaryocytes (with 
normal distribution). 
DISCUSSION
Small lymphocytic lymphoma is an indolent form of 
B-cell NHL.10 Historically, B-SLL was considered a 
different disease from B-chronic lymphocytic leukemia 
(CLL). They are now considered as different manifesta-
tions of the same disease and are grouped together in 
the World Health Organization (WHO) classification 
of NHL.11 The median survival of patients with SLL/
CLL is 10 years and most patients are asymptomatic 
at diagnosis.12,13 Most patients with SLL/CLL do not 
require treatment at presentation unless they have a 
cytopenia or organ dysfunction.14 By definition, an ab-
solute lymphocyte count of <5×109/L has been used 
to distinguish SLL from CLL, but this is now consid-
ered an artificial distinction.14 Other differences include 
lower rates of cytogenetic abnormalities, higher rates of 
CD38 expression, and mutated IgVH gene status with 
SLL compared to CLL.15 Both diseases are treated with 
the same type of chemotherapy regimen using rituximab 
and nucleoside analogues with FCR (fludarabine, cyclo-
phosphamide, rituximab) being the most popular regi-
men used in the US. Based on 1985-2005 cumulative 
data from M.D. Anderson Cancer Center, the response 
rate, survival, event-free survival, and adverse prognostic 
features are comparable between SLL and CLL.15
Some autoimmune diseases seem to increase the 
risk of developing NHL. Although this association is 
established for rheumatoid arthritis and Sjogren syn-
drome, it is still debated in other diseases like SSc.7 
Figure 1. biopsy of cervical lymph node showing diffuse 
proliferation of small lymphocytes with effaced architecture of 
the lymph node. 
Figure 2. CT scan of the chest, abdomen, and pelvis showing 
mediastinal and mesenteric adenopathy.
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On a recent systematic review, risk factors for malig-
nancy in patients with SSc were old age, female gen-
der, and diffuse skin involvement (DcSSc).16 Vettori 
et al. recently published a systematic review of all 
cases of NHL reported in association with SSc; 20 
cases were identified by searching MEDLINE from 
1959-2009.17 Of those 20 cases, only 5 suffered from 
LcSSc.18-22 Different manifestations of the full-blown 
CREST syndrome were described in these cases and 
occasional overlap with other systemic manifestations 
of scleroderma18-22 were also reported, like scleroderma 
renal crisis.19 The subtypes of NHL reported were all 
of the B-cell type and included histiocytic lymphoma 
of the colon,20 the Pinkus variant of skin and muscle,21 
SLL,19 mucosa-associated lymphoid tissue (MALT) 
lymphoma of the salivary gland22 and Helicobacter 
pylori-associated gastric MALT lymphoma.18 The 
duration between the presentation of SSc and NHL 
was as little as 1.5 years up to 11 years17 and some oc-
curred simultaneously raising the possibility that SSc 
could be considered a “paraneoplastic” manifestation 
of NHL.23 T-cell NHL cases were reported in asso-
ciation with DcSSc but not with LcSSc.24,25 The as-
sociation between SSc and NHL may be incidental or 
secondary to an emergence of a malignant clone from 
a pool of polyclonal chronically stimulated B-cells,26 
deficiency of T- and NK-cells,26-28 or common genetic 
backgrounds that predisposes to both disorders, like 
the HLA-DR5 haplotype.29
To our knowledge, there have been no reports of a 
small lymphocytic lymphoma (SLL) in association with 
LcSSc/CREST syndrome. The other peculiar features of 
this case were the development of SLL while the patient 
was receiving cyclophosphamide, the remarkable com-
plete response rate to nucleoside analogue-based chemo-
therapy despite the presence of the 17p deletion (indica-
tive of activation of the p53 tumor-suppressor gene and 
potential resistance of nucleoside analogues),30 and the 
presence of all the classic features of the CREST syn-
drome. The stabilization of lung function after chemo-
therapy, and rituximab, suggests that the malignant lym-
phocyte clone could be instrumental in the pathogenesis 
of lung injury through the production of autoantibodies 
or through presentation of auto-antigens to T-cells. 
A series of recent studies of rituximab in a few pa-
tients with scleroderma showed improvement in der-
mal hyalinized collagen content, dermal myofibroblast 
numbers,31,32 and pulmonary function.33,34 Treatment 
with rituximab was well tolerated in these studies.32,33 
Reactivation of the JC virus leading to progressive mul-
tifocal leukoencephalopathy (PML) is a rare but devas-
tating complication that has been reported in patients 
with B-cell NHLs after treatment with rituximab.35 
Rituximab is usually combined with chemotherapy 
and its role in JC virus reactivation, independent of 
the immune suppressive effect of chemotherapy, is 
unclear. In December 2006, the US Food and Drug 
Administration released an alert for rituximab after 2 
patients with SLE developed PML and died after off-
label treatment with rituximab.36 The role of JC virus 
reactivation, and development of PML, after rituximab 
treatment for rheumatologic condition is also unclear 
as these patients had usually received multiple immune 
suppressive agents in the past. 
The authors declare no conflict of interest.
Figure 3. bone marrow biopsy showing marrow involvement with small mature 
lymphocyte aggregates (top panel). immunohistochemical stains were positive for Cd5 
(bottow right) and Cd20 (bottom left).
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